Vandria SA published phase I data on a potential new mechanism of action in treating Alzheimer’s disease, demonstrating its orally available and brain-penetrant mitochondria-boosting compound, VNA-318 ...

Glucagon-like peptide-1 (GLP-1) receptor agonists clearly help patients shed pounds, but many regain all - or more - of the weight once they discontinue the medications. Fractyl Health Inc. could ...

So much for stability at the U.S. FDA. Three weeks after accepting the position as director of the FDA’s CDER, Richard Pazdur has informed the agency of his intention to retire at the end of the year.

Hightide Therapeutics Inc.’s berberine ursodeoxycholate (HTD-1801) met the primary endpoint showing superior improvements in ...

Bao Pharmaceuticals Co. Ltd., a developer of subcutaneous biologic drugs, priced its IPO at HK$26.38 on Dec. 2, aiming to raise about HK$1 billion (US$128 million). Bao expects net proceeds of HK$921.

I love the idea of ‘micropublications’ (preparing one now),” the neurobiologist Oded Rechavi commented on social media in July. The term clearly suggests a short article, and although the publishing ...

China’s National Medical Products Administration gave the nod to Innovent Biologics Inc.’s picankibart (IBI-112), branded as Pecondle, for treating moderate to severe plaque psoriasis in adults who ...

Attention has turned to the regulatory path worldwide after Belite Bio Inc. unveiled positive top-line data from the phase III Dragon study with oral, daily tinlarebant in Stargardt disease type 1, ...

Proving its latest addition to the Farapulse pulsed field ablation (PFA) platform is no turkey, Boston Scientific Corp.'s Farapoint PFA catheter received CE mark as the U.S. celebrated Thanksgiving.

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing Cookie Settings ...

HIV since at least the advent of antiretroviral therapy. In a report on “Overcoming disruption, transforming the AIDS ...

Ascletis Pharma Inc. has selected ASC-37 oral tablets as a clinical development candidate for the treatment of obesity. The company expects to submit an IND application to the FDA in the second ...